Ann: Botanix Investor Presentation, page-87

Regarding the time frame for a Phase 3 progression announcement following the EOP2 meeting, the short answer is I don't know. The company is required to send the FDA Ph2 data and Ph3 plans prior to the meeting for pre-assessment and I'm sure this would help expedite an outcome however it would depend on what feedback, recommendations and subsequent amendments to the Ph3 plan come from that.

As @runaway stated, the meeting will happen regardless of Ph2 result and while a positive EOP2 outcome to progress to Ph3 would no doubt help the SP, one would assume majority of the rerate would have already occurred IF the Ph2 results were positive basis natural assumption Ph3 is a given at that point anyway.

Let "The Hunt For Green October" begin.